Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2736032 | 0.83 | NAMPT (0.33) | NAMPT | |
| SCHEMBL10361609 | 0.73 | NAMPT (0.33) | NAMPTSOS1 | |
| SCHEMBL23277737 | 0.71 | — | — | |
| SCHEMBL15505977 | 0.71 | PDPK1 (0.40) | NAMPT | |
| SCHEMBL20224786 | 0.70 | SOS1 (0.32) | SOS1 | |
| SCHEMBL9944699 | 0.70 | NAMPT (0.35) | NAMPT | |
| SCHEMBL15505981 | 0.68 | P2RX7 (0.33) | — | |
| SCHEMBL18702115 | 0.67 | NAMPT (0.44) | NAMPT | |
| SCHEMBL15241310 | 0.66 | NAMPT (0.37) | NAMPT | |
| SCHEMBL18629994 | 0.66 | NAMPT (0.35) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827656-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20180155340-A1 | QUINOLONE DERIVATIVES AS FGFR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2018-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827656-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | NAMPT 3332/4885SOS1 4548/4885 |
| US-20180155340-A1 | QUINOLONE DERIVATIVES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | NAMPT 720/4885SOS1 1486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.